Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995 Jul;39(7):1554-8.
doi: 10.1128/AAC.39.7.1554.

Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus

Affiliations

Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus

L Ferrero et al. Antimicrob Agents Chemother. 1995 Jul.

Erratum in

  • Antimicrob Agents Chemother. 1995 Oct;39(10):2373

Abstract

Fluoroquinolone-resistant mutants were obtained in vitro from Staphylococcus aureus RN4220 by stepwise selection on increasing concentrations of ciprofloxacin. Results from sequence analysis of the quinolone resistance-determining region of GyrA and of the corresponding region of GrlA, the DNA topoisomerase IV subunit, showed an alteration of Ser-80 to Tyr (corresponding to Ser-83 of Escherichia coli GyrA) or Glu-84 to Lys in GrlA of both low- and high-level quinolone-resistant mutants. Second-step mutants were found to have, in addition to a mutation in grlA, reduced accumulation of norfloxacin or an alteration in GyrA at Ser-84 to Leu or Glu-88 to Lys. Third-step mutants derived from second-step mutants with reduced accumulation were found to have a mutation in gyrA. The results from this study demonstrated that mutations in gyrA or mutations leading to reduced drug accumulation occur after alteration of GrlA, supporting the previous findings (L. Ferrero, B. Cameron, B. Manse, D. Lagneaux, J. Crouzet, A. Famechon, and F. Blanche, Mol. Microbiol. 13:641-653, 1994) that DNA topoisomerase IV is a primary target of fluoroquinolones in S. aureus.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Bacteriol. 1990 Dec;172(12):6942-9 - PubMed
    1. Antimicrob Agents Chemother. 1990 Jun;34(6):1271-2 - PubMed
    1. J Infect Dis. 1991 May;163(5):1080-6 - PubMed
    1. J Bacteriol. 1991 Sep;173(18):5854-60 - PubMed
    1. J Antimicrob Chemother. 1991 Nov;28(5):639-53 - PubMed

MeSH terms

LinkOut - more resources